Studies of TKI therapy for pediatric CML
| TKI . | Sponsor and collaborator . | Phase . | Year published . | Author and references . |
|---|---|---|---|---|
| Imatinib | COG | 1 | 2004 | Champagne33 |
| Imatinib | COG | 2 | 2012 | Champagne34 |
| Imatinib | French | 4 | 2011 | Millot35 |
| Dasatinib | COG | 1 | 2011 | Aplenc36 |
| Dasatinib | BMS/ITCC | 1 | 2013 | Zwaan37 |
| Dasatinib | BMS | 2 | Unpublished | www.clinicaltrials.gov (#NCT00777036)38 |
| Nilotinib | Novartis | 1 | Unpublished | www.clinicaltrials.gov (#NCT01077544) |
| Nilotinib | Novartis/COG/ITCC | 2 | Unpublished | www.clinicaltrials.gov (#NCT01844765) |
| TKI . | Sponsor and collaborator . | Phase . | Year published . | Author and references . |
|---|---|---|---|---|
| Imatinib | COG | 1 | 2004 | Champagne33 |
| Imatinib | COG | 2 | 2012 | Champagne34 |
| Imatinib | French | 4 | 2011 | Millot35 |
| Dasatinib | COG | 1 | 2011 | Aplenc36 |
| Dasatinib | BMS/ITCC | 1 | 2013 | Zwaan37 |
| Dasatinib | BMS | 2 | Unpublished | www.clinicaltrials.gov (#NCT00777036)38 |
| Nilotinib | Novartis | 1 | Unpublished | www.clinicaltrials.gov (#NCT01077544) |
| Nilotinib | Novartis/COG/ITCC | 2 | Unpublished | www.clinicaltrials.gov (#NCT01844765) |
BMS, Bristol-Myers Squibb; CML, chronic myelogenous leukemia; COG, Children’s Oncology Group; ITCC, Innovative Therapies for Children with Cancer Consortium.